STOCK TITAN

Aprea Therapeutics Inc - APRE STOCK NEWS

Welcome to our dedicated news page for Aprea Therapeutics (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aprea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aprea Therapeutics's position in the market.

Rhea-AI Summary
Aprea Therapeutics, Inc. announces positive pre-clinical findings for APR-1051, a WEE1 kinase inhibitor, indicating potential as a treatment for Cyclin E-overexpressing cancers. The company also received IND clearance for APR-1051 and presented details on the planned Phase 1 trial. ATRN-119, a novel ATR inhibitor, shows promising safety and tolerability in an ongoing study with preliminary signs of clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
Rhea-AI Summary
Aprea Therapeutics, Inc. (APRE) reports financial results for Q4 and full year 2023, highlighting progress in synthetic lethality-based cancer therapeutics. The company plans to complete dose escalation of ATRN-119 and generate human efficacy data in H2 2024. FDA cleared IND for APR-1051, initiating Phase 1 trial in H1 2024. Aprea raised $16 million in private placement financing in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
-
Rhea-AI Summary
Aprea Therapeutics, Inc. announces a financing round led by Sphera Healthcare, raising $34.0 million in total gross proceeds. The funding will support clinical trials for synthetic lethality treatments in cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
none
Rhea-AI Summary
Aprea Therapeutics, Inc. announces FDA clearance for Phase 1 clinical trial of APR-1051, a highly selective WEE1 inhibitor for Cyclin E overexpressing cancers. The company plans to evaluate safety, tolerability, and efficacy in patients with advanced solid tumors, including breast and ovarian cancers, with an update expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
-
Rhea-AI Summary
Aprea Therapeutics, Inc. announces four poster presentations at the AACR Annual Meeting, covering ATRN-119 and APR-1051. The presentations focus on the first-in-human phase 1 study of APR-1051 and the phase 1/2a trial of ATRN-119. Additionally, the posters highlight the potential of APR-1051 as a treatment for cyclin E-overexpressing cancers and the synergistic effect of a novel ATR inhibitor with lomustine for glioblastoma treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
Rhea-AI Summary
Aprea Therapeutics, Inc. has submitted an Investigational New Drug (IND) application to the FDA for APR-1051, an oral inhibitor of WEE1 kinase. The company believes APR-1051 is potentially differentiated from other WEE1 inhibitors and has demonstrated highly potent anti-tumor activity in pre-clinical studies. Pending FDA clearance, Aprea plans to commence clinical testing in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.97%
Tags
Rhea-AI Summary
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that Dr. Oren Gilad, President and CEO, will deliver a presentation at the 7th DDR Inhibitors Summit in Boston, MA. The company is focused on precision oncology through synthetic lethality and looks forward to providing an update to the oncology community at the summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
-
Rhea-AI Summary
Aprea Therapeutics, Inc. (Nasdaq: APRE) provided a corporate update on their pipeline of DNA Damage Response (DDR) anti-cancer agents, highlighting the progress made in the ongoing Phase 1/2a clinical trial of ATRN-119 and the submission of the IND for APR-1051, a next-generation WEE1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary
Aprea Therapeutics, Inc. (Nasdaq: APRE) reported financial results for the three and nine months ended September 30, 2023, and provided a business update. The company highlighted the progress of its ATR inhibitor, ATRN-119, in solid tumors, and its WEE1 inhibitor, ATRN-1051. Key milestones include the completion of dose escalation for ATRN-119 in 1Q 2024 and the initiation of the dose expansion study in 2Q 2024. Financially, the company reported cash and cash equivalents of $25.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
Rhea-AI Summary
Aprea Therapeutics will host a KOL event on October 31, 2023, featuring Dr. Fiona Simpkins and Dr. Timothy A. Yap. They will discuss treatments and investigational drugs for patients with advanced solid tumors. Aprea will also discuss its Phase 1/2a study evaluating ATRN-119 and its pre-clinical WEE1 inhibitor, ATRN-1051. A live Q&A session will follow the presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
Aprea Therapeutics Inc

Nasdaq:APRE

APRE Rankings

APRE Stock Data

31.77M
4.19M
11.67%
17.7%
1.95%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Doylestown

About APRE

annan naturvetenskaplig och teknisk forskning och utveckling